Skip to content Skip to footer
Tris Pharma

Tris Pharma’s Onyda XR Gains the US FDA’s Approval for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) 

Shots:  The US FDA has granted approval to the company’s QD extended-release oral suspension of Onyda XR (clonidine hydrochloride) with nighttime dosing alone or as adj. to approved central nervous system (CNS) stimulant therapies for ADHD treatment in children (≥6yrs.). Its availability is anticipated in H2’24  The approval was supported by the data from studies…

Read more

ThoughtSpot_Carla Adams8

ADHD Treatment Options: Therapy, Medication, and More

Attention-Deficit/Hyperactivity Disorder (ADHD) is a common neurological condition that affects both children and adults. It manifests as inattention, impulsivity, and hyperactivity that impact daily functioning and development. Finding the right treatment is crucial as it can greatly improve the individual's ability to function and their quality of life. Treatment options are diverse, ranging from various…

Read more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]